Maternal RSV vax gets green light for NIP listing

Pfizer’s bivalent vaccine Abrysvo is indicated for pregnant women at 24-36 weeks’ gestation in addition to over-60s.
Rachel Fieldhouse

Pregnant women could soon have subsidised access to the bivalent respiratory syncytial virus vaccine Abrysvo, just two months after it was approved by the TGA.

The PBAC has recommended listing the vaccine on the National Immunisation Program (NIP) to prevent lower respiratory tract illness in infants from birth until six months of age via maternal immunisation.